Refractory Multiple Myeloma Market is projected to witness lucrative growth by reaching up to USD 3.4 billion by 2031 | Major Companies - Bristol Myers Squibb, Pfizer Inc., GSK plc., Novartis AG.

Market Size and Growth:

The Global Refractory Multiple Myeloma Market Size reached USD 2.4 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 3.4 billion by 2031. The Market is expected to exhibit a CAGR of 4.7% during the forecast period 2024-2031. According to DataM Intelligence Report.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/refractory-multiple-myeloma-market?sz

The Refractory Multiple Myeloma Market refers to the healthcare segment focused on diagnosing, managing, and treating patients whose multiple myeloma no longer responds to standard therapies. It includes advanced drug classes, novel targeted therapies, immunotherapies, supportive care solutions, and research advancements aimed at improving survival, reducing relapse, and addressing unmet clinical needs in this hard-to-treat cancer population.

United States: Recent Developments of Refractory Multiple Myeloma Market

✅ October 2025: FDA approved belantamab mafodotin-blmf (Blenrep) combined with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least two prior therapies, including a proteasome inhibitor and immunomodulatory agent.​

✅ September 2025: Johnson & Johnson announced promising results from an investigational regimen of TECVAYLI (teclistamab) and DARZALEX FASPRO for induction treatment in multiple myeloma, showing 100% MRD negativity in evaluable patients.​

✅ September 2025: MMRF presented novel research data at IMS 2025 demonstrating impacts from flagship programs on relapsed/refractory multiple myeloma.​

Europe: Recent Developments of Refractory Multiple Myeloma Market

✅ November 2025: NICE recommended TALVEY (talquetamab) as monotherapy for adults with relapsed and refractory multiple myeloma after three or more prior therapies.​

✅ September 2025: CellCentric dosed first patients in Phase 1/2 trial of inobrodib combined with bispecifics (teclistamab or elranatamab) for relapsed/refractory myeloma, with initial safety data expected end of 2025.​

✅ September 2025: IMS 2025 featured updates on relapsed/refractory multiple myeloma, including real-world data and advancing T-cell redirecting strategies.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/refractory-multiple-myeloma-market?sz

FDA & Regulatory Approvals in (2025):

Linvoseltamab-gcpt - FDA accelerated approval (Jul 2, 2025):

✅ A BCMA-directed CD3 bispecific T-cell engager received accelerated approval for adults with relapsed or refractory multiple myeloma after ≥4 prior lines (PI, IMiD, anti-CD38). This adds another off-the-shelf bispecific option against BCMA and comes with a REMS for immune/neurologic toxicities.

Blenrep (belantamab mafodotin) combinations - UK/MHRA approval for relapsed/refractory MM (April 2025):

✅ GSK reported MHRA approvals for combination use in relapsed/refractory settings - expands utility of an antibody-drug conjugate in RRMM outside the US.

Other noteworthy regulatory moves affecting myeloma treatment options (contextual):

✅ FDA expanded/approved frontline or combo indications for other anti-CD38/anti-SLAMF7 agents earlier in 2025 (broadening the treatment landscape that RRMM therapies must compete with).

Mergers & Acquisitions and Big Licensing Deals in (2025):

Bristol Myers Squibb (BMS) - acquisition of 2seventy bio (~$286M, announced Mar 11, 2025):

✅ BMS bought 2seventy (the Abecma CAR-T partner/spinoff) to internalize cell-therapy manufacturing/profits for Abecma (a marketed anti-BCMA CAR-T for myeloma). This consolidates CAR-T assets and may affect pricing/availability and competitive positioning vs other BCMA therapies.

AbbVie - exclusive licensing pact with Ichnos/Glenmark for ISB-2001 (Jul 2025):

✅ AbbVie licensed ISB-2001 (a cancer candidate in Phase 1 for relapsed/refractory MM) with a large upfront and milestone structure, strengthening AbbVie's myeloma/oncology pipeline via an external R&D partner.

Large oncology/cell-therapy buyouts that influence mm ecosystem (H1-2025):

✅ Major pharma continued to buy cell-therapy and oncology plays (e.g., AstraZeneca deals and other oncology M&A) - this trend increases big-pharma competition for next-gen myeloma assets (CAR-T, bispecifics, ADCs). Representative reporting and sector summaries in 2025 show elevated oncology M&A activity.

Major Players:

Key companies in the Refractory Multiple Myeloma market include:

Bristol Myers Squibb
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Janssen Global Services, LLC
Gilead Sciences, Inc.
Fresenius Kabi
GSK plc.
Novartis AG
Takeda Pharmaceutical Company Limited
Genentech, Inc.

Segments Covered in the Refractory Multiple Myeloma Market:

By Drug Type: Proteasome Inhibitor, Immunomodulators, Anti-CD38 Monoclonal Antibody, Others.

By Route of Administration: Oral, Parenteral.

By Product Type: Tablet, Capsule, Solution, Suspension.

By End User: Hospitals, Surgical Centers/ Clinics, Others.

Regional Analysis for Refractory Multiple Myeloma Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=refractory-multiple-myeloma-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Refractory Multiple Myeloma market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Refractory Multiple Myeloma Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Refractory Multiple Myeloma market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Refractory Multiple Myeloma Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Industry Related Reports:

Myeloproliferative Disorders Drugs Market: https://www.datamintelligence.com/download-sample/myeloproliferative-disorders-drugs-market?sz

Myelofibrosis Therapeutics Market: https://www.datamintelligence.com/download-sample/myelofibrosis-therapeutics-market?sz

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Refractory Multiple Myeloma market?

➠ Who are the global key manufacturers of the Refractory Multiple Myeloma Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Refractory Multiple Myeloma market opportunities and threats faced by the vendors in the global Refractory Multiple Myeloma Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Refractory Multiple Myeloma market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.